Clinical Trial

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
Protocol Amendment History 39 amendments
This ClinicalTrials.gov record has been amended 39 times since 2022-06-29; most recent amendment 2026-07-20.
Status change: Enrolling by Invitation → Active, Not Recruiting 2023-12-21
Status change: Recruiting → Enrolling by Invitation 2023-02-17
Status change: Not Yet Recruiting → Recruiting 2022-11-17
Trial Details
NCT Number NCT05444257
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Cystic Fibrosis
Enrollment 822 participants
Start Date 2022-11-08
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-21